{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-319441","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.154320+00:00","generated_at":"2026-05-16T13:16:05.095256+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics raises ~$1.7M in registered direct offering at $0.33/share with warrants","bullets":["Sold 5,227,275 shares at $0.33/share; gross proceeds ~$1.7M; closing expected Dec 16, 2025.","Concurrent private placement of warrants to buy 5,227,275 shares at $0.33, exercisable only after stockholder approval, 5-year term.","CEO and prior purchaser entered voting agreements to support warrant share issuance under Nasdaq rules.","Placement agent H.C. Wainwright receives 7% cash fee and 365,909 warrants at $0.4125 per share.","Net proceeds for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-319441","json":"https://secwatch.observer/filing/0001193125-25-319441.json","markdown":"https://secwatch.observer/filing/0001193125-25-319441.md","text":"https://secwatch.observer/filing/0001193125-25-319441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525319441/0001193125-25-319441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525319441/fblg-20251214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:16:05.095256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6312cfdd250b0c3bc4d6237663dd70a11c11878a","claim":"FibroBiologics, Inc. issued warrants to purchase up to 365,909 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (placement agent) for services as placement agent.","evidence_excerpt":"the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 365,909 shares of Common Stock), at an exercise price of $0.4125 per share (the \"Placement Agent Warrants\").","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525319441/0001193125-25-319441-index.htm","confidence":0.98,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"warrants to purchase up to 365,909 shares of Common Stock"},{"label":"Purchaser","value":"H.C. Wainwright & Co., LLC (placement agent)"},{"label":"Consideration","value":"services as placement agent"}],"fact_type":"equity_issuance"},{"claim_id":"6321df9047b863c93e51c7e078a046bee9066af1","claim":"FibroBiologics, Inc. issued 5,227,275 shares of Common Stock underlying Warrants of warrant to institutional investors for no additional consideration beyond the Purchase Agreement; exercise price $0.33 per share.","evidence_excerpt":"5,227,275 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.33 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue to the Purchasers, in a concurrent private placement, warrants to purchase one","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525319441/0001193125-25-319441-index.htm","confidence":0.98,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"5,227,275 shares of Common Stock underlying Warrants"},{"label":"Purchaser","value":"institutional investors"},{"label":"Consideration","value":"no additional consideration beyond the Purchase Agreement; exercise price $0.33 per share"}],"fact_type":"equity_issuance"},{"claim_id":"cd27d99009d430b2e792993c3707c10deb08eacf","claim":"FibroBiologics, Inc. issued 5,227,275 shares of common stock to institutional investors for gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses.","evidence_excerpt":"approval as described below. The exercise price of the Warrants is $0.33 per share. The gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses payable by the Company. In addition, if the holders of the unregistered Warrants exercise such Warrants in full for","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525319441/0001193125-25-319441-index.htm","confidence":0.98,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"5,227,275 shares"},{"label":"Purchaser","value":"institutional investors"},{"label":"Consideration","value":"gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses"}],"fact_type":"equity_issuance"},{"claim_id":"c3139afff1620ac8688082bae872d1f4ca1388eb","claim":"FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.7 million (effective 2025-12-14).","evidence_excerpt":"On December 14, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 5,227,275 shares (the “Shares”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525319441/0001193125-25-319441-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $1.7 million"},{"label":"Effective","value":"2025-12-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}